Abstract 174P
Background
Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival of <12%. Patients typically present with advanced disease. Developing a blood-based screening panel could offer a simple test without requiring invasive procedures, enabling earlier detection and accelerate drug discovery. This study integrated plasma-based proteomic, tissue and clinical data supported by the PURPLE pancreatic cancer registry to identify novel biomarkers that can aid screening for early-stage disease, predict survival outcomes and guide drug discovery.
Methods
Unbiased quantitative comparative proteomics analysis was performed via a 16-window diaPASEF method on a TIMS TOF Pro mass spectrometer. Data was searched with DIA-NN (v1.8.3) in library-free mode and normalisation using RUVIIIC (v1.0.19). Matched clinicopathological and survival data was extracted from the PURPLE pancreatic cancer registry.
Results
Proteomic analysis of plasma from 203 participants showed distinct protein changes between PDAC patients with early and late-disease stage. Plasma from 120 PDAC, 69 healthy controls and 14 alternative pancreatic pathologies were analysed. A total of 919 proteins were detected (mean of 400 in each sample). When comparing PDAC with healthy controls, 246 significant differentially expressed proteins were identified (false discovery rate, FDR <0.1). Hierarchical data clustering analysis demonstrated a clear protein signature of the top 40 differentially expressed proteins in PDAC. When comparing early versus late-stage PDAC, 12 significantly differentially expressed proteins were identified. Reactome pathway analysis revealed significant up-regulation in immune response and wound healing pathways, and down-regulation of lipid and glucose metabolism in PDAC. These findings suggest that abnormal processes are quantifiable and can be detected earlier in the blood.
Conclusions
A unique PDAC protein signature was identified when comparing PDAC to healthy controls and alternative pancreatic pathologies. The dysregulated proteins identified have potential therapeutic implications that could accelerate selection of drug targets, inform clinical trial design, and enable earlier blood-based PDAC screening.
Clinical trial identification
Australian New Zealand Clinical Trial Registy Trial Acronym: PURPLE Registry Pancreatic cancer: Understanding Routine Practice and Lifting End Results (PURPLE). A Prospective Pancreatic Cancer Clinical Registry Registration number: ACTRN12617001474347 Registered: 08/03/2017.
Editorial acknowledgement
Legal entity responsible for the study
Walter & Eliza Hall Institute.
Funding
Hemstritch Centenary Fellowship ( Awarded to Dr Belinda Lee), Philanthropic funding from the Hemstritch Foundation & Segal Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
373P - Investigating the impact of treatment on geriatric patients with locally advanced head and neck squamous cell carcinoma
Presenter: Yen Ting Liu
Session: Poster Display
Resources:
Abstract
374P - Immunohistochemical evaluation of oral lichen planus: A prospective clinical study
Presenter: Saravanan Sampoornam Pape
Session: Poster Display
Resources:
Abstract
375P - Survival and prognostic factors of head and neck squamous cell carcinoma patients treated with either definitive CCRT or post operative CCRT with platinum-based chemotherapy in Rajavithi hospital, Thailand
Presenter: wanit samadee
Session: Poster Display
Resources:
Abstract
376P - Nutrition as an independent prognostic factor in locally advanced nasopharyngeal carcinoma: A retrospective cohort study and propensity score-matched analysis
Presenter: haizhen yi
Session: Poster Display
Resources:
Abstract
377P - Oropharyngeal squamous cell carcinomas in Indian population: P16 positivity and treatment outcomes following chemoradiotherapy
Presenter: Parth Verma
Session: Poster Display
Resources:
Abstract
378P - A real-world retrospective analysis of the efficacy of pembrolizumab combined with chemotherapy as neoadjuvant treatment for locally advanced head and neck squamous cell carcinoma (LA HNSCC)
Presenter: zhu Liu
Session: Poster Display
Resources:
Abstract
379P - Nimotuzumab in combination with chemoradiation for patients with intermediate stage and locally advanced nasopharyngeal carcinoma: A retrospective comparative analysis using 5-year real-world survival data
Presenter: Andhika Rachman
Session: Poster Display
Resources:
Abstract
380P - An epidemiological analysis on the prevalence of oral cancer and its awareness among Irula tribes of South India
Presenter: Delfin Lovelina Francis
Session: Poster Display
Resources:
Abstract
381P - P16INK4 over-expression, early stages, keratinization, and surgical margin-free status are associated with better prognosis of oral squamous cell carcinoma (OSCC)
Presenter: Sumadi Lukman Anwar
Session: Poster Display
Resources:
Abstract
382P - Oral health disparities in privileged and underprivileged tribes of south India: A study of the prevalence of precancerous oral lesions
Presenter: Shanavas Palliyal
Session: Poster Display
Resources:
Abstract